Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05801978 · ClinicalTrials.gov registry record · Phase 4
Durability of Vaccine Responses
A Phase 4 study of Vaccine Response, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 66
- Enrollment target
- 3
- Study locations
NCT05801978: Recruiting Phase 4 study of Vaccine Response, sponsored by Emory University.
NCT05801978 is a Phase 4 study of Vaccine Response that is actively recruiting participants, run by Emory University. The registered enrollment target is 66 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (87% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05801978, a Phase 4 study of Vaccine Response, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 66 participants
- Enrollment target
- 3
- Study locations
Study Summary
The ability of the vaccines today to generate a long-lasting protection against infections varies greatly from one vaccine to another. The yellow fever vaccine (YF-17D) is one of the most successful vaccines ever developed, having been administered to over 600 million people globally. A single vaccination is known to induce durable protection over several decades. In contrast, the quadrivalent influenza vaccine (QIV) generates an immunity that wanes quickly with no long-lasting protection. Currently, the duration of immune protection for new vaccines is difficult to predict during vaccine product development and can only be ascertained by a "wait and see" approach. This is due, in part, to the fact that some of the signals that activate a durable immune system protection remain unknown. This study aims to provide a better understanding of this problem by vaccinating willing participants with either the FDA-approved yellow fever vaccine or the quadrivalent influenza vaccine and collecting baseline and follow-up biologic samples to compare how the immune system reacts.
Primary Outcome
Magnitude of neutralizing antibody responses against YF-17D at 270 days after vaccination among participants who receive YF-17D.
Conditions Studied
Interventions
- BIOLOGICAL Live Attenuated Yellow Fever 17D Vaccine
- BIOLOGICAL Quadrivalent seasonal influenza vaccine
Study Locations (3)
Georgia
- Emory University Hospital - Atlanta
- Emory Winship Cancer Institute - Atlanta
- The Hope Clinic of Emory University - Decatur
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2023-04-11 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 4 |
What NCT05801978 shows while recruiting
NCT05801978 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Vaccine Response appearing as the primary indexed condition, and to 2 interventions - of which Live Attenuated Yellow Fever 17D Vaccine is the first listed.
NCT05801978 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT05801978 about?
NCT05801978 is a clinical study titled "Durability of Vaccine Responses". The ability of the vaccines today to generate a long-lasting protection against infections varies greatly from one vaccine to another. The yellow fever vaccine (YF-17D) is one of the most successful vaccines ever developed, having been administered to over 600 million people globally. A single vacci...
What is the current status of trial NCT05801978?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 66 participants. The study started on 2023-04-11. Estimated completion is 2026-09-30.
What conditions does trial NCT05801978 study?
This clinical trial studies the following conditions: Vaccine Response.
What interventions are being tested in trial NCT05801978?
The interventions under investigation include: Live Attenuated Yellow Fever 17D Vaccine (BIOLOGICAL), Quadrivalent seasonal influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05801978?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05801978 being conducted?
This trial has 3 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vaccine Response
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05801978's enrollment target sits among peer trials
66 1083rd of 2000 higher than 911 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI